Drug discovery

Novo Nordisk head office
#Artificial intelligence (AI) #Collaboration #Drug discovery #Novo Nordisk #OpenAI

Novo Nordisk partners with OpenAI across operations

Novo Nordisk has announced a strategic partnership with OpenAI that it hopes will place the company at the forefront of AI transformation in healthcare and help it bring new and better treatment options to patients faster.  The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug… Read More

#Business & Investment #News

Antibody-drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Learn how to streamline ADC discovery

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, available on-demand, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers,… Read More

Webinar date:
Supported by BioDuro
#News

Biomarkers concept
#Biomarkers #Drug discovery #eBook

eBook: The Full Guide to Precision Medicine

A new eBook is now available for DDW readers to download for free. In ‘The Full Guide to Precision Medicine’ sponsored by Evotec, readers can discover how biomarkers transform drug discovery and clinical development across the R&D continuum. What you will learn about: Understand biomarker types and their role in decision-making… Read More

#News

Swiss Biotech Day 2026
#Biotech #Drug discovery #Events #Switzerland

Register now for Swiss Biotech Day 2026

Swiss Biotech Day, first launched in 2021, will be held this year at Congress Center Basel on 4-5 May.  The event has seen remarkable growth every year and has become a key global biotechnology conference for life sciences professionals, fostering international collaboration and impactful partnerships.  … Read More

#News

#AI #Chemify #Drug discovery

Chemify’s drug discovery platform validated by papers

A platform helping drug discovery companies take a novel concept to makeable compound has been validated in three academic papers.  Chemify says its Chemputation platform, which integrates AI- and ML-driven molecular discovery and automated robotic synthesis, has been validated as a new paradigm for how small molecule-drugs and materials are discovered, designed and manufactured. … Read More

#News

Brain Awareness Week
#Depression #Drug discovery #Neuroscience #Psychedelics

Designing scalable psychedelic therapies for treatment‑resistant depression 

Kevin Craig, Chief Medical Officer of AtaiBeckley, discusses the current therapeutic landscape for major depressive disorder and therapeutic advances for this hard-to-treat disease.   Major depressive disorder (MDD), or depression, remains one of the most urgent and complex challenges in mental health. More than 300 million people1 worldwide live with the condition, but a substantial proportion of these people – commonly estimated at 30-502– do… Read More

#Exclusive Content

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Overcome the hurdles in ADC discovery

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, available on-demand, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers,… Read More

Webinar date:
Supported by BioDuro
#News

3D protein molecules structure
#Drug development #Drug discovery #Protein degradation #Protein targets

Breaking through the undruggable barrier with TPDs

Alex Bentley, an 1851 Industrial Fellow working with GSK and the University of Strathclyde, discusses how his research into protein degraders will benefit drug discovery efforts across the pharmaceutical industry.  First proposed in the early 2000s, targeted protein degradation (TPD) has emerged as a therapeutic modality with the potential to transform the… Read More

#Exclusive Content

Antibody-drug conjugates
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Practical insights on accelerating ADC discovery

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, available on-demand, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers,… Read More

Webinar date:
Supported by BioDuro
#News

Antibody-drug conjugates
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Accelerating ADC discovery through strategically integrated chemistry, biology, and DMPK

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar demonstrates how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers, and payload selection,… Read More

Webinar date:
Supported by BioDuro
#Webinars

Hematopoietic stem cells in bone marrow.
#Biopharma #Drug development #Drug discovery #Hematopoietic stem cells #Stem cells

Kinetic stem cell counting: a new method to support therapeutic development 

James L Sherley, MD, PhD, explores how a new method for quantifying stem cells in mesenchymal tissue samples can lead to better drug development for stem cell therapies.   Mesenchymal tissue cell samples are considered incredibly promising for the development of new stem cell therapies. These samples can be based on bone marrow,… Read More

#Exclusive Content

#Coiled Therapeutics #Drug discovery #Oncology #Precision medicine

Coiled Therapeutics completes transition to clinical-stage company

Coiled Therapeutics, previously Roquefort Therapeutics, has completed the acquisition of the exclusive worldwide licence to AO-252 and admitted its shares to trading on the AIM Market of the London Stock Exchange.  Admission follows a successful fundraise of £8.5 ($11.3) million through the issue of 85,000,000 New Ordinary Share with institutional… Read More

#Business & Investment #News #Start-up Zone

Antibodies
#Antibodies #Biotech #Drug discovery #In Focus Report

The opportunities & challenges for antibody-based therapies

Download this In Focus report to learn about the market for antibody-based therapies and the scientific developments behind recent advances in these drugs. Read about: Where investment lies in the antibody-based drugs market Why mAbs are at the heart of phasing out animal testing The data bottleneck in AI antibody… Read More

#News

#Cancer research #Drug discovery #Enzymes #Myeloma #Parkinson's #University of Edinburgh

DDW Highlights: 26 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer enzyme discovery provided clues for potential new treatments. Elsewhere, how can… Read More

#Podcasts